as well as AstraZeneca and partner Sanofi’s SNY respiratory syncytial virus (“RSV”) antibody Beyfortus (nirsevimab). AstraZeneca records 50% share of gross profits on sales of Beyfortus in ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus, the brand name for the antibody medication nirsevimab. (AstraZeneca/The Associated Press) Babies born ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next year for nirsevimab, an antibody designed to prevent respiratory syncytial virus (RSV ...

Key presentations include data on Beyfortus (nirsevimab), AstraZeneca’s long-acting antibody for RSV, demonstrating that the treatment does not interfere with RSV detection using rapid antigen tests.

If approved, clesrovimab’s main competitor will be AstraZeneca and Sanofi’s Beyfortus (nirsevimab), which is approved in the US for preventing RSV lower respiratory tract disease (LRTD ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €645 million in the third quarter, significantly more than €18 million in the previous quarter.

The data, revealed at IDWeek 2024 in Los Angeles, positions clesrovimab as a potential rival to the RSV market leader, Sanofi (Euronext: SAN) and AstraZeneca's (LSE: AZN) Beyfortus (nirsevimab). The ...